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Abstract
In this single-blind study, the effects of acute oral admin-
istration of high-dose Hypericum perforatum extract WS
5570 on the cortisol (COR), adrenocorticotropic hormone
(ACTH), growth hormone (GH), and prolactin (PRL) se-
cretions were examined in 12 healthy male volunteers. In
a randomized order, the subjects received placebo or
WS 5570 at several dosages (600, 900, and 1,200 mg) at
08.00 h on 4 different days. After insertion of an intrave-
nous catheter, blood samples were drawn 1 h prior to
administration of placebo or WS 5570 (600, 900, or 1,200
mg), at the time of administration, and during 5 h there-
after at intervals of 30 min. The serum concentrations of
COR, GH, and PRL as well as the plasma levels of ACTH
were determined in each blood sample by means of dou-
ble antibody radioimmunoassay, fluoroimmunoassay,
and chemiluminescence immunometric assay methods.
The area under the curve value was used as parameter
for COR, ACTH, GH, and PRL responses. Repeated-mea-
sures Anova revealed a significant stimulatory effect of
WS 5570 on the ACTH secretion, whereas COR and PRL
secretions were not significantly influenced. Moreover,
there was a stimulatory peak of GH release 240 min after
challenge with WS 5570 in some but not all volunteers,
without reaching statistical significance in comparison
with placebo. Mean arterial blood pressure and heart
rate remained unchanged after administration of WS
5570. Apparently, WS 5570 at the dosages given in this
study inconsistently causes endocrinological effects in
healthy subjects by influencing central neurotransmit-
ters.
Copyright © 2004 S. Karger AG, Basel
Introduction
Preparations from Hypericum perforatum (St. John’s
wort; SJW) extracts have been shown in most studies to be
efficacious in mild to moderate depression [1, 2]. How-
ever, the exact mechanism of action has not been suffi-
ciently clarified yet. Earlier findings suggesting mono-
amine oxidase inhibiting effects of the constituents hyper-
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icin or pseudohypericin [3] could not be replicated in later
studies [4]. In more recent research, the focus of attention
has been directed towards the role of the components
hyperforin and adhyperforin for antidepressant efficacy.
While neither hypericin nor the flavonol glycoside
kaempferol show any reuptake-inhibiting properties, hy-
perforin and its structural analogue adhyperforin have
been identified as the only reuptake-inhibiting constitu-
ents of SJW extracts in synaptosomal preparations [5].
Apparently, hyperforin and adhyperforin have a broad
inhibitory profile [reuptake inhibition of serotonin (5-
HT), noradrenaline, and dopamine, but also of Á-amino-
butyric acid and L-glutamate] and do not act as competi-
tive inhibitors at the neurotransmitter-binding sites of the
transporter proteins, but affect the sodium gradient,
thereby causing an uptake inhibition [6, 7]. Moreover,
according to a clinical study performed in depressive
patients, an important role of hyperforin for the antide-
pressant action of SJW extracts has been suggested [8].
To further examine the effects of SJW extracts on the
central aminergic systems in vivo, our research group
investigated the neuroendocrine effects of the hyperforin-
containing SJW extract WS 5570 at lower dosages (300
and 600 mg p.o.) in a former study [9], using the neuroen-
docrine challenge paradigm. This paradigm is based on
the involvement of monoamine pathways in the control of
anterior pituitary hormone secretion [10] and has been
described extensively [11]. In the former investigation [9],
WS 5570 caused a weak but significant cortisol (COR)
stimulation in a dose-dependent manner (COR stimula-
tion after 600 mg, but not after 300 mg WS 5570). In con-
trast to a study performed by Franklin et al. [12], who
administered the SJW extract LI 160 at a high dosage
(2,700 mg p.o.), in our former investigation [9], the stimu-
latory effects of WS 5570 on the growth hormone (GH)
secretion were inconsistent, and no inhibitory influence of
WS 5570 on the prolactin (PRL) secretion was seen. To
test the hypothesis that these conflicting and inconsistent
endocrinological findings are due to the different dosages
used and to answer the question whether increased dos-
ages of WS 5570 would also cause an enhanced stimulato-
ry impact on COR and/or GH secretion in a dose-depen-
dent manner, we performed the present study using WS
5570 at higher dosages (600, 900, and 1,200 mg) in
healthy male volunteers.
Subjects and Methods
Study Population and Study Design
Twelve healthy male subjects having a normal weight, age range
26–41 (meanB SEM 32.08 B 4.80) years, were included upon
receipt of their informed consent, following a clinical examination
(psychiatric and medical history, physical examination) and estab-
lishment of normal laboratory and clinical parameters: hemoglobin,
K+, Na+, glutamic-oxaloacetic transaminase, glutamic-pyruvic trans-
aminase, Á-glutamyltransferase, blood glucose, bilirubin, serum cre-
atinine, heart rate, electrocardiogram and electroencephalogram. Al-
cohol abstinence 24 h prior to each experiment and abstinence from
medication beginning 4 weeks before the study were mandatory.
Each subject took part four times in the trial. In a randomized
order, the volunteers received placebo or the H. perforatum ex-
tract WS 5570 (600, 900, or 1,200 mg) orally on 4 different days. At
07.00 h, an intravenous catheter was inserted into the antecubital
vein and kept open with physiological saline solution. The subjects
rested in bed throughout the experiments (up to t = 300 min). At t =
–60 min (07.00 h), at t = 0 min (08.00 h; administration of placebo or
WS 5570), and at intervals of 30 min thereafter up to t = 300 min
(13.00 h), blood was drawn. The subjects fasted from completion of
the evening meal the day before until conclusion of the experiment.
The study was carried out according to the fifth revision of the
Declaration of Helsinki [13] and had been approved by an ethics
committee.
Endocrinological and Blood Pressure Measurements
Serum and plasma samples were separated by centrifugation as
soon as possible, frozen at –80 °C, and stored for determination of
the hormone concentrations. The serum concentrations of COR,
GH, and PRL and the plasma concentrations of adrenocorticotropic
hormone (ACTH) were determined in each blood sample. The COR,
GH, and PRL levels were determined by means of double-antibody
radioimmunoassay (RIA) and fluoroimmunoassay methods. The
sensitivity (‘minimal detectable dose’) of the commercially available
immunoassay kits was approximately 6.1 nmol/l for the COR RIA
(Diagnostic Products Corporation, Los Angeles, Calif., USA),
4.5 pmol/l for the GH fluoroimmunoassay (DELFIA® hGH; Perkin-
Elmer, Torrrance, Calif., USA), and 1.74 pmol/l for the PRL fluoro-
immunoassay (DELFIA® Prolactin). The specificity was very high
for the immunoassays with an extremely low cross-reactivity to other
natural hormones; the percent cross-reactivity to other naturally
occurring steroids in quality control tests (apparent concentrations
related to the amount added in the experiment) was up to 6.8% for
the COR RIA (although some steroids exhibit slight cross-reactivity,
their normal phyiological concentrations are low as compared with
COR so as not to significantly interfere in the double-antibody COR
procedure), 0.1% for the GH fluoroimmunoassay, and !0.01% for
the PRL fluoroimmunoassay. The total variation (% CV) was 6.6%
for the COR RIA, 3.9% for the GH fluoroimmunoassay, and 2.7%
for the PRL fluoroimmunoassay. ACTH was measured using a
chemiluminescence immunometric assay (Nichols, San Juan Capis-
trano, Calif., USA); the lower detection limit of this assay is
0.11 pmol/l, intra- and interassay CVs are below 4 and 7%, respec-
tively.
The blood pressure (diastolic pressure = RRdia; systolic pressure =
RRsys) was measured by the Riva-Rocci method every 30 min. The
mean arterial blood pressure (MAP) was calculated according to the
equation MAP = RRdia +1/3 (RRsys – RRdia) and served as parameter
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Table 1. Influence of placebo and WS 5570 on COR, ACTH, GH, and PRL secretions and on MAP and heart rate in 12 healthy male subjects
(mean B SEM)
COR AUC0–300 ACTH AUC0–300 GH AUC0–300 PRL AUC0–300 MAP AUC0–300 Heart rate AUC0–300
nmol/l ! min pmol/l ! min pmol/l ! min pmol/l ! min mmHg ! min beats/min ! min
Placebo 60,911.58B4,800.52 1,578.26B126.11 8,001.09B1,974.80 61,346.46B7,766.26 26,553.89B566.37 18,342.50B883.41
600 mg WS 5570 61,537.36B3,628.78 1,858.43B166.67 16,156.72B6,198.09 56,877.87B8,146.21 27,306.89B631.11 18,409.17B752.56
900 mg WS 5570 60,593.40B3,330.35 1,856.21B141.90 15,699.57B6,333.69 56,586.61B7,245.91 26,781.10B782.42 18,333.33B986.83
1,200 mg WS 5570 64,108.54B3,359.15 1,953.42B130.69 13,475.55B5,039.50 60,018.42B9,496.78 26,771.26B737.08 18,507.50B899.83
for assessing the blood pressure effects of WS 5570. Furthermore, the
heart rate (beats/min) was recorded every 30 min.
Data Analysis
In addition to the descriptive and graphical evaluation of the
mean curves (hormonal concentrations, MAP, heart rate), the areas
under the curve (AUCs, 0–300 min) were calculated according to the
method of Friedman [14], representing the total COR, ACTH, GH,
and PRL secretions and total MAP and heart rate following oral
administration of placebo or WS 5570 (600, 900, and 1,200 mg). For
statistical comparisons of hormonal secretions (COR, ACTH, GH,
and PRL AUCs) and vital parameters (MAP, heart rate), analysis of
variance (Anova) with a repeated-measures design (Wilks’ multivar-
iate tests of significance) was performed, considering ‘treatment’ (ad-
ministration of placebo or WS 5570 at the different dosages) as with-
in-subjects factor with four levels (placebo, 600 mg WS 5570, 900 mg
WS 5570, and 1,200 mg WS 5570). For those hormonal or vital
parameters with a significant ‘treatment’ effect, additionally tests
with contrasts were performed. As a nominal level of significance,
alpha = 0.05 was accepted. To keep the type I error equal to 0.05,
tests with contrasts were performed at a reduced level of significance
(alpha adjusted according to the Bonferroni procedure).
Results
COR and ACTH Secretions
Using Anova with a repeated-measures design (Wilks’
multivariate tests of significance), no significant influence
of ‘treatment’ (placebo, 600 mg WS 5570, 900 mg WS
5570, and 1,200 mg WS 5570) on the COR secretion
could be demonstrated (F = 0.634; d.f. = 3, 9; significance
of F = 0.612; table 1, fig. 1). Nevertheless, there was a sig-
nificant ‘treatment’ effect on the ACTH secretion (F =
4.061; d.f. = 3, 9; significance of F = 0.044), i.e., the
ACTH release depended significantly on the type of treat-
ment (placebo and WS 5570 at the different dosages),
being the lowest after administration of placebo (ACTH
AUC0–300 1,578.26 B 126.11 pmol/l ! min) and the high-
est after 1,200 mg WS 5570 (ACTH AUC0–300 1,953.42 B
130.69 pmol/l ! min; table 1, fig. 1). However, using the
Bonferroni procedure for alpha adjustment post hoc tests
with contrasts did not show any significant differences in
ACTH AUC0–300 values between the four treatment con-
ditions.
GH Secretion
Descriptively, both the GH AUC0–300 values and the
mean values were higher after administration of WS 5570
at all dosages (600, 900, and 1,200 mg) as compared with
placebo (table 1, fig. 1). In most cases, the GH stimulation
was observed more than 150 min after administration of
WS 5570. However, GH-stimulatory effects occurred in-
consistently after WS 5570 was given. When regarding
50 pmol/l GH as minimum peak value, only part of the
subjects reached this GH peak concentration after admin-
istration of WS 5570 (600 mg: 5 out of 12 subjects; 900
mg: 7 out of 12 subjects; 1,200 mg: 8 out of 12 subjects).
Repeated-measures Anova did not reveal a significant
‘treatment’ effect on GH AUC0–300 values (F = 0.560;
d.f. = 3, 9; significance of F = 0.655). Nor was there any
significant ‘treatment’ effect, if only GH concentrations
from t = 150 min up to t = 300 min after administration of
placebo or WS 5570 were taken into consideration (GH
AUC150–300 values: F = 1.113; d.f. = 3, 9; significance of
F = 0.394).
PRL Secretion
PRL AUC0–300 values and PRL mean values were
comparable after administration of placebo and WS 5570
(600, 900, and 1,200 mg; table 1, fig. 1). No significant
‘treatment’ effect could be demonstrated (F = 0.334; d.f. =
3, 9; significance of F = 0.802).
MAP and Heart Rate
Neither the MAP nor the heart rate were significantly
influenced by administration of placebo or WS 5570 at
the different dosages (MAP AUC0–300: F = 0.673; d.f. = 3,
9; significance of F = 0.590; heart rate AUC0–300: F =
0.144; d.f. = 3, 9; significance of F = 0.931).
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Fig. 1. Mean values B SEM of COR (a), ACTH (b), GH (c), and PRL (d) concentrations and of MAP (e) and heart
rate (f) after oral administration of placebo (j), 600 mg WS 5570 (d), 900 mg WS 5570 (P), and 1,200 mg WS 5570
($) in 12 healthy male subjects. Statistical significance at the p ! 0.05 level in repeated-measures Anova indicated.
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Discussion
In the present study, the impact of the hyperforin-con-
taining SJW extract WS 5570 at higher dosages (600, 900,
and 1,200 mg) on anterior pituitary hormone secretion
and on vital parameters was investigated in 12 healthy
male subjects. We could only partially replicate our form-
er finding of stimulatory effects of WS 5570 on the hypo-
thalamic-pituitary-adrenocortical axis activity [9], in that
there was a significant stimulatory ‘treatment’ effect of
WS 5570 on the ACTH secretion but not on the COR
secretion in the present study. Since hyperforin and adhy-
perforin have been identified as the reuptake-inhibiting
components of SJW extracts in in vitro investigations
using synaptosomal preparations [6, 7], one may assume
that these constituents are responsible for influencing
aminergic systems and causing endocrinological effects in
the neuroendocrine challenge paradigm. According to an-
imal [15] and human [11] studies, ACTH and COR stim-
ulation by noradrenaline and/or 5-HT reuptake-inhib-
iting antidepressants may be mediated via agonistic ef-
fects of noradrenaline and 5-HT on hypothalamic ·1, 5-
HT1, and 5-HT2 receptors, thereby enhancing hypotha-
lamic corticotropin-releasing hormone and/or vasopres-
sin release. Apparently, the dosages of WS 5570 used in
the present study (600, 900, and 1,200 mg) were not suffi-
cient to cause consistently a stimulatory impact on ACTH
and COR secretions. Similarly, Franklin and coworkers
found stimulatory effects of the hyperforin-containing
SJW extract LI 160 on the COR secretion in some but not
all healthy volunteers. In an unblinded pilot study of this
research group [16], a significant increase of the salivary
COR concentrations in 6 healthy males after oral admin-
istration of 2,700 mg LI 160 was found. However, when
giving 2,700 mg LI 160 orally to 12 healthy subjects in a
double-blind placebo-controlled study, elevated COR lev-
els were seen only in 4 out of the 12 subjects, without
reaching statistical significance [12].
As in our former study [9], some but not all volunteers
were prone to show a certain increase of the GH secretion
after administration of WS 5570 which may be due to ·2-
adrenergic or dopaminergic actions at the hypothalamic
level, leading to an enhanced GH-releasing hormone
release. However, neither statistical significance nor dose
dependency could be demonstrated in our new investiga-
tion. Interestingly, the weak GH-stimulatory effects in
some participants in our study occurred more than 150
min after administration of WS 5570, with a maximum
at t = 240 min (fig. 1). Franklin et al. [12] also found
GH stimulation after the SJW extract LI 160 was given
(2,700 mg p.o.); in contrast to our investigation, the GH-
stimulatory effects reached statistical significance in com-
parison with placebo. In this context, pharmacokinetic
observations have to be considered. First, in man the
hyperforin plasma levels began to increase not until 60
min after administration of the respective SJW extract,
reaching a peak maximum at t = 210 min [12], which may
explain the delay of some stimulatory effects, e.g., the
weak GH stimulation in some individuals of our study
more than 150 min after the challenge. Second, after
administration of 2,700 mg LI 160 to healthy volunteers,
the mean hyperforin plasma peak was nearly 1,500 ng/ml
[12], whereas in a pharmacokinetic study performed by
Biber et al. [17], administration of 300, 600, and 1,200 mg
WS 5570 led to lower maximal plasma hyperforin concen-
trations in the subjects (mean peak values 153, 302, and
437 ng/ml, respectively), suggesting that the inconsistent
GH stimulation in our study may be a matter of dosage
and bioavailability of hyperforin.
As opposed to the study performed by Franklin et al.
[12], no significant inhibitory effects of the SJW extract
WS 5570 on the PRL secretion could be demonstrated in
our investigation. Whereas the PRL secretion is increased
by enhancement of the serotonergic function [11], the
PRL release is reduced by dopamine as a potent PRL
release inhibiting factor [18]. Since hyperforin has been
proven to be a reuptake inhibitor of both 5-HT and dopa-
mine [4], opposing effects with regard to the PRL secre-
tion may play a role. The presumption that the relevance
of serotonergic and dopaminergic mechanisms for the reg-
ulation of PRL secretion is dose dependent may be the
explanation for the different results in our study and in
the investigation performed by Franklin et al. [12]. More-
over, it is conceivable that in our study, the dosage was
too low to cause serotonergic and/or dopaminergic effects
on the PRL release.
The missing of significant changes in vital parameters
(blood pressure, heart rate) and the missing of side effects
or adverse events confirm the good tolerability of the SJW
extract WS 5570 at the dosages given in the present study
(up to 1,200 mg p.o.). Additionally, no case of photosensi-
tivity was observed in our study which is one of the possi-
ble side effects of SJW extracts reported in the literature
[19].
Taken together, the SJW extract WS 5570, given at
dosages which were in part higher than the dose usually
administered in the treatment of depressive symptoms (3
! 300 mg per day), caused some weak and inconsistent
endocrinological effects in healthy subjects. Our findings
raise the question whether the therapeutically recom-
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mended dosages of SJW extracts are adequate to lead to a
sufficient impact on central neurotransmitter systems.
Moreover, there is a need for standardization of possibly
therapeutically active constituents of SJW extracts such
as hyperforin or adhyperforin to establish evidence-based
dosage guidelines.
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